Compass Therapeutics, Inc.
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing antibody-based therapeutics for people with cancer. Its research focuses on angiogenesis, the immune system and tumor growth. The company has four clinical-stage product candidates: tovecimig, a bispecific antibody targeting DLL4 and VEGF-A; CTX-471, an antibody targeting CD137; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1; and CTX-10726, a bispecific antibody targeting PD-1 and VEGF-A. It is also developing additional candidates. Compass advances its candidates through clinical development and commercialization, as standalone therapies or in combinations, and may pursue strategic partnerships for selected candidates. It has licensed global rights to tovecimig outside South Korea and licenses antibodies for CTX-471. Compass Therapeutics is headquartered in Boston, Massachusetts.
No enriched coverage for $CMPX in the last 7 days.
No SEC Form 4 filings for $CMPX in the last 30 days.
See all $CMPX insider activity →Compass Therapeutics (CMPX) reported positive Phase 2/3 results for tovecimig in biliary tract cancer, meeting primary and key secondary endpoints. ORR improved to 18.0% vs 5.3%, and PFS to 4.7 vs 2.6 months. Data was published in the Journal of Clinical Oncology and presented at ESMO. The safety profile was consistent with prior studies.
Beyond Air (XAIR) director bought $56,590 in shares, Compass Therapeutics (CMPX) CFO acquired $18,400 in stock, Sky Harbour (SKYH) CFO purchased $15,040 in shares. CrowdStrike (CRWD) president sold $64M, Medpace (MEDP) CEO sold $30M, Snowflake (SNOW) director sold $17M. Insider trades may indicate confidence or tax obligations.
Lerner Neil (Chief Accounting Officer) purchased 20,000 shares of Compass Therapeutics, Inc. (CMPX) at $0.92 on 2026-10-01.
Recent CMPX coverage spans financial news, regulation and insider activity.
The trial data suggests meaningful clinical benefit, likely prompting a price rally.
Strong buying signal for CMPX.
Insider purchase may signal confidence, but the small size limits market impact.
Small insider purchase may signal confidence but size is negligible for price impact.
Downgrade may pressure stock.
AlphAI scores every news story that mentions CMPX with an AI model for sentiment and relevance, and aggregates insider trades from Compass Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Compass Therapeutics (CMPX) reported positive Phase 2/3 results for tovecimig in biliary tract cancer, meeting primary and key secondary endpoints. ORR improved to 18.0% vs 5.3%, and PFS to 4.7 vs 2.6 months. Data was published in the Journal of Clinical Oncology and presented at ESMO. The safety profile was consistent with prior studies.
1 min readBeyond Air (XAIR) director bought $56,590 in shares, Compass Therapeutics (CMPX) CFO acquired $18,400 in stock, Sky Harbour (SKYH) CFO purchased $15,040 in shares. CrowdStrike (CRWD) president sold $64M, Medpace (MEDP) CEO sold $30M, Snowflake (SNOW) director sold $17M. Insider trades may indicate confidence or tax obligations.
3 min readLerner Neil (Chief Accounting Officer) purchased 20,000 shares of Compass Therapeutics, Inc. (CMPX) at $0.92 on 2026-10-01.
1 min readLerner Neil (Chief Accounting Officer) purchased 2,500 shares of Compass Therapeutics, Inc. (CMPX) at $1.14 on 2026-09-24.
1 min readStifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.
2 min readCompass Therapeutics (CMPX) shares dropped 6% after FDA recommended additional trials for Tovecimig. Analysts cut price targets; H.C. Wainwright to $12, Wedbush to $1. Compass plans BLA submission in Q1 2027 despite FDA concerns. Stock down 76% YTD, trading at $1.2.
2 min readStifel maintained a Buy rating and $6.00 price target for Compass Therapeutics (CMPX), citing positive regulatory feedback on tovecimig. The stock is down 81% from its 52-week high, trading at $1.31. The company plans a 2027 biologics license application and has a current ratio of 11.22, despite cash burn. Stifel noted undervaluation and upcoming catalysts.
1 min readCompass Therapeutics (CMPX) shares fell over 25% after the FDA recommended an additional trial for its cancer drug Tovecimig, potentially delaying its marketing application. The FDA wants a trial demonstrating improved overall survival in advanced biliary tract cancer patients. Compass disagrees and plans further discussions. The company has $180 million in cash, expected to last into 2028. CMPX shares traded at over 2-year lows.
7 min readCompass Therapeutics (CMPX) shares dropped 40.8% to $1.51 in premarket trading after the FDA recommended an additional trial for tovecimig, an experimental cancer treatment. The company disagrees and plans to continue discussions with the FDA.
1 min readCompass Therapeutics, Inc. (CMPX) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig. Compass does not believe that a new
2 min read
